

SCORE Search Results Details for Application 10552515 and Search Result 20090316_151740_us-10-552-515-1_copy_157_933.oligo8.rag.

Score Home	Retrieve Application	SCORE System	SCORE	Comments /
Page	List	Overview	FAQ	Suggestions

This page gives you Search Results detail for the Application 10552515 and Search Result 20090316_151740_us-10-552-515-1_copy_157_933.oligo8.rag.

[Go Back to previous page](#)

GenCore version 6.3
Copyright (c) 1993 - 2009 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: March 17, 2009, 20:56:54 ; Search time 133 Seconds
(without alignments)
4899.431 Million cell updates/sec

Title: US-10-552-515-1_COPY_157_933
Perfect score: 777
Sequence: 1 QQDVQDGNTTVHYALLSASW.....SELSSHWTPTFTVPKASQLQQ 777

Scoring table: OLIGO
Gapop 60.0 , Gapext 60.0

Searched: 4548778 seqs, 838641292 residues

Word size : 8

Total number of hits satisfying chosen parameters: 11

Minimum DB seq length: 8
Maximum DB seq length: 10

Post-processing: Listing first 45 summaries

Database : A_Geneseq_200812:*
1: geneseqp:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query		DB	ID	Description
		Match	Length			
1	9	1.2	9	1	ADT77668	Adt77668 Splice va
2	9	1.2	9	1	ADT77673	Adt77673 Splice va
3	9	1.2	9	1	ADT77670	Adt77670 Splice va
4	9	1.2	9	1	ADT77671	Adt77671 Splice va
5	9	1.2	9	1	ADT77666	Adt77666 Splice va
6	9	1.2	9	1	ADT77669	Adt77669 Splice va
7	9	1.2	9	1	ADT77672	Adt77672 Splice va
8	9	1.2	9	1	ADT77667	Adt77667 Splice va
9	8	1.0	10	1	AAG95042	Aag95042 Human com
10	8	1.0	10	1	AAG97554	Aag97554 Human com
11	8	1.0	10	1	AAG97553	Aag97553 Human com

ALIGNMENTS

RESULT 1

ADT77668

ID ADT77668 standard; peptide; 9 AA.

XX

AC ADT77668;

XX

DT 13-JAN-2005 (first entry)

XX

DE Splice variant-novel gene expressed in prostate (SV-NGEP) epitope.

XX

KW Splice variant-novel gene expressed in prostate; SV-NGEP; human;
prostate cancer; cytostatic; gene therapy; immunotherapy; epitope.

XX

OS Homo sapiens.

XX

PN WO2004092213-A1.

XX

PD 28-OCT-2004.

XX

PF 05-APR-2004; 2004WO-US010588.

XX

PR 08-APR-2003; 2003US-0461399P.

XX

PA (USSH) US DEPT HEALTH & HUMAN SERVICES.

XX

PI Pastan I, Bera TK, Lee B;

XX

DR WPI; 2004-758338/74.

XX

PT New Splice Variant-Novels Gene Expressed in Prostate polypeptide or
 PT encoding nucleic acid molecule for diagnosing, preventing or treating
 PT cancer, especially prostate cancer.

XX

PS Disclosure; SEQ ID NO 5; 88pp; English.

XX

CC The present sequence is that of a predicted epitope of human splice
 CC variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope
 CC is predicted to bind HLA2-01 and was identified using an HLA binding
 CC motif program. It corresponds to amino acids 170-178 of SV-NGEP.
 CC Polypeptides comprising an immunogenic fragment of 8 consecutive amino
 CC acids of SV-NGEP which specifically bind to an antibody that specifically
 CC binds a polypeptide comprising amino acids 157-933 of SV-NGEP are
 CC claimed. The invention provides methods for: detecting prostate cancer in
 CC a subject by contacting a sample with an antibody that specifically binds
 CC a SV-NGEP polypeptide and detecting the formation of an immune complex,
 CC or detecting an increase in expression of SV-NGEP polypeptide or mRNA;
 CC producing an immune response against a cell expressing SV-NGEP, for
 CC example in a subject with prostate cancer, by administering SV-NGEP
 CC polypeptide or polynucleotide to produce an immune response that
 CC decreases growth of the prostate cancer; inhibiting the growth of a
 CC malignant cell that expresses SV-NGEP by culturing cytotoxic T
 CC lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting
 CC these with the malignant cell; and inhibiting the growth of a malignant
 CC cell by contact with an antibody that specifically binds SV-NGEP, where
 CC the antibody is linked to a chemotherapeutic agent or toxin.

XX

SQ Sequence 9 AA;

Query Match 1.2%; Score 9; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 3.9e+06;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 14 ALLSASWAV 22
 |||||
 Db 1 ALLSASWAV 9

RESULT 2

ADT77673

ID ADT77673 standard; peptide; 9 AA.

XX

AC ADT77673;

XX

DT 13-JAN-2005 (first entry)

XX

DE Splice variant-novel gene expressed in prostate (SV-NGEP) epitope.

XX

KW Splice variant-novel gene expressed in prostate; SV-NGEP; human;

KW prostate cancer; cytostatic; gene therapy; immunotherapy; epitope.
 XX
 OS Homo sapiens.
 XX
 PN WO2004092213-A1.
 XX
 PD 28-OCT-2004.
 XX
 PF 05-APR-2004; 2004WO-US010588.
 XX
 PR 08-APR-2003; 2003US-0461399P.
 XX
 PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
 XX
 PI Pastan I, Bera TK, Lee B;
 XX
 DR WPI; 2004-758338/74.
 XX
 PT New Splice Variant-Novel Gene Expressed in Prostate polypeptide or
 PT encoding nucleic acid molecule for diagnosing, preventing or treating
 PT cancer, especially prostate cancer.
 XX
 PS Disclosure; SEQ ID NO 10; 88pp; English.
 XX
 CC The present sequence is that of a predicted epitope of human splice
 CC variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope
 CC is predicted to bind HLA2-01 and was identified using an HLA binding
 CC motif program. It corresponds to amino acids 562-570 of SV-NGEP.
 CC Polypeptides comprising an immunogenic fragment of 8 consecutive amino
 CC acids of SV-NGEP which specifically bind to an antibody that specifically
 CC binds a polypeptide comprising amino acids 157-933 of SV-NGEP are
 CC claimed. The invention provides methods for: detecting prostate cancer in
 CC a subject by contacting a sample with an antibody that specifically binds
 CC a SV-NGEP polypeptide and detecting the formation of an immune complex,
 CC or detecting an increase in expression of SV-NGEP polypeptide or mRNA;
 CC producing an immune response against a cell expressing SV-NGEP, for
 CC example in a subject with prostate cancer, by administering SV-NGEP
 CC polypeptide or polynucleotide to produce an immune response that
 CC decreases growth of the prostate cancer; inhibiting the growth of a
 CC malignant cell that expresses SV-NGEP by culturing cytotoxic T
 CC lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting
 CC these with the malignant cell; and inhibiting the growth of a malignant
 CC cell by contact with an antibody that specifically binds SV-NGEP, where
 CC the antibody is linked to a chemotherapeutic agent or toxin.
 XX
 SQ Sequence 9 AA;

Query Match 1.2%; Score 9; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 3.9e+06;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 406 KIYVSLAHV 414
 |||||
 Db 1 KIYVSLAHV 9

RESULT 3

ADT77670

ID ADT77670 standard; peptide; 9 AA.

XX

AC ADT77670;

XX

DT 13-JAN-2005 (first entry)

XX

DE Splice variant-novel gene expressed in prostate (SV-NGEP) epitope.

XX

KW Splice variant-novel gene expressed in prostate; SV-NGEP; human;
 KW prostate cancer; cytostatic; gene therapy; immunotherapy; epitope.

XX

OS Homo sapiens.

XX

PN W02004092213-A1.

XX

PD 28-OCT-2004.

XX

PF 05-APR-2004; 2004WO-US010588.

XX

PR 08-APR-2003; 2003US-0461399P.

XX

PA (USSH) US DEPT HEALTH & HUMAN SERVICES.

XX

PI Pastan I, Bera TK, Lee B;

XX

DR WPI; 2004-758338/74.

XX

PT New Splice Variant-Novel Gene Expressed in Prostate polypeptide or
 PT encoding nucleic acid molecule for diagnosing, preventing or treating
 PT cancer, especially prostate cancer.

XX

PS Disclosure; SEQ ID NO 7; 88pp; English.

XX

CC The present sequence is that of a predicted epitope of human splice
 CC variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope
 CC is predicted to bind HLA2-01 and was identified using an HLA binding
 CC motif program. It corresponds to amino acids 557-565 of SV-NGEP.
 CC Polypeptides comprising an immunogenic fragment of 8 consecutive amino
 CC acids of SV-NGEP which specifically bind to an antibody that specifically
 CC binds a polypeptide comprising amino acids 157-933 of SV-NGEP are

CC claimed. The invention provides methods for: detecting prostate cancer in
 CC a subject by contacting a sample with an antibody that specifically binds
 CC a SV-NGEP polypeptide and detecting the formation of an immune complex,
 CC or detecting an increase in expression of SV-NGEP polypeptide or mRNA;
 CC producing an immune response against a cell expressing SV-NGEP, for
 CC example in a subject with prostate cancer, by administering SV-NGEP
 CC polypeptide or polynucleotide to produce an immune response that
 CC decreases growth of the prostate cancer; inhibiting the growth of a
 CC malignant cell that expresses SV-NGEP by culturing cytotoxic T
 CC lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting
 CC these with the malignant cell; and inhibiting the growth of a malignant
 CC cell by contact with an antibody that specifically binds SV-NGEP, where
 CC the antibody is linked to a chemotherapeutic agent or toxin.

XX

SQ Sequence 9 AA;

Query Match 1.2%; Score 9; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 3.9e+06;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 401 ILILSKIYV 409

|||||

Db 1 ILILSKIYV 9

RESULT 4

ADT77671

ID ADT77671 standard; peptide; 9 AA.

XX

AC ADT77671;

XX

DT 13-JAN-2005 (first entry)

XX

DE Splice variant-novel gene expressed in prostate (SV-NGEP) epitope.

XX

KW Splice variant-novel gene expressed in prostate; SV-NGEP; human;
 KW prostate cancer; cytostatic; gene therapy; immunotherapy; epitope.

XX

OS Homo sapiens.

XX

PN WO2004092213-A1.

XX

PD 28-OCT-2004.

XX

PF 05-APR-2004; 2004WO-US010588.

XX

PR 08-APR-2003; 2003US-0461399P.

XX

PA (USSH) US DEPT HEALTH & HUMAN SERVICES.

XX
 PI Pastan I, Bera TK, Lee B;
 XX
 DR WPI; 2004-758338/74.
 XX
 PT New Splice Variant-Novels Gene Expressed in Prostate polypeptide or
 PT encoding nucleic acid molecule for diagnosing, preventing or treating
 PT cancer, especially prostate cancer.
 XX
 PS Disclosure; SEQ ID NO 8; 88pp; English.
 XX
 CC The present sequence is that of a predicted epitope of human splice
 CC variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope
 CC is predicted to bind HLA2-01 and was identified using an HLA binding
 CC motif program. It corresponds to amino acids 258-266 of SV-NGEP.
 CC Polypeptides comprising an immunogenic fragment of 8 consecutive amino
 CC acids of SV-NGEP which specifically bind to an antibody that specifically
 CC binds a polypeptide comprising amino acids 157-933 of SV-NGEP are
 CC claimed. The invention provides methods for: detecting prostate cancer in
 CC a subject by contacting a sample with an antibody that specifically binds
 CC a SV-NGEP polypeptide and detecting the formation of an immune complex,
 CC or detecting an increase in expression of SV-NGEP polypeptide or mRNA;
 CC producing an immune response against a cell expressing SV-NGEP, for
 CC example in a subject with prostate cancer, by administering SV-NGEP
 CC polypeptide or polynucleotide to produce an immune response that
 CC decreases growth of the prostate cancer; inhibiting the growth of a
 CC malignant cell that expresses SV-NGEP by culturing cytotoxic T
 CC lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting
 CC these with the malignant cell; and inhibiting the growth of a malignant
 CC cell by contact with an antibody that specifically binds SV-NGEP, where
 CC the antibody is linked to a chemotherapeutic agent or toxin.
 XX
 SQ Sequence 9 AA;

Query Match 1.2%; Score 9; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 3.9e+06;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 102 ILFEILAKT 110

|||||||

Db 1 ILFEILAKT 9

RESULT 5

ADT77666

ID ADT77666 standard; peptide; 9 AA.

XX

AC ADT77666;

XX

DT 13-JAN-2005 (first entry)
 XX
 DE Splice variant-novel gene expressed in prostate (SV-NGEP) epitope.
 XX
 KW Splice variant-novel gene expressed in prostate; SV-NGEP; human;
 KW prostate cancer; cytostatic; gene therapy; immunotherapy; epitope.
 XX
 OS Homo sapiens.
 XX
 PN W02004092213-A1.
 XX
 PD 28-OCT-2004.
 XX
 PF 05-APR-2004; 2004WO-US010588.
 XX
 PR 08-APR-2003; 2003US-0461399P.
 XX
 PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
 XX
 PI Pastan I, Bera TK, Lee B;
 XX
 DR WPI; 2004-758338/74.
 XX
 PT New Splice Variant-Novel Gene Expressed in Prostate polypeptide or
 PT encoding nucleic acid molecule for diagnosing, preventing or treating
 PT cancer, especially prostate cancer.
 XX
 PS Disclosure; SEQ ID NO 3; 88pp; English.
 XX
 CC The present sequence is that of a predicted epitope of human splice
 CC variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope
 CC is predicted to bind HLA2-01 and was identified using an HLA binding
 CC motif program. It corresponds to amino acids 427-435 of SV-NGEP.
 CC Polypeptides comprising an immunogenic fragment of 8 consecutive amino
 CC acids of SV-NGEP which specifically bind to an antibody that specifically
 CC binds a polypeptide comprising amino acids 157-933 of SV-NGEP are
 CC claimed. The invention provides methods for: detecting prostate cancer in
 CC a subject by contacting a sample with an antibody that specifically binds
 CC a SV-NGEP polypeptide and detecting the formation of an immune complex,
 CC or detecting an increase in expression of SV-NGEP polypeptide or mRNA;
 CC producing an immune response against a cell expressing SV-NGEP, for
 CC example in a subject with prostate cancer, by administering SV-NGEP
 CC polypeptide or polynucleotide to produce an immune response that
 CC decreases growth of the prostate cancer; inhibiting the growth of a
 CC malignant cell that expresses SV-NGEP by culturing cytotoxic T
 CC lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting
 CC these with the malignant cell; and inhibiting the growth of a malignant
 CC cell by contact with an antibody that specifically binds SV-NGEP, where
 CC the antibody is linked to a chemotherapeutic agent or toxin.

XX

SQ Sequence 9 AA;

Query Match 1.2%; Score 9; DB 1; Length 9;

Best Local Similarity 100.0%; Pred. No. 3.9e+06;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 271 SLFMALWAV 279

|||||

Db 1 SLFMALWAV 9

RESULT 6

ADT77669

ID ADT77669 standard; peptide; 9 AA.

XX

AC ADT77669;

XX

DT 13-JAN-2005 (first entry)

XX

DE Splice variant-novel gene expressed in prostate (SV-NGEP) epitope.

XX

KW Splice variant-novel gene expressed in prostate; SV-NGEP; human;

KW prostate cancer; cytostatic; gene therapy; immunotherapy; epitope.

XX

OS Homo sapiens.

XX

PN WO2004092213-A1.

XX

PD 28-OCT-2004.

XX

PF 05-APR-2004; 2004WO-US010588.

XX

PR 08-APR-2003; 2003US-0461399P.

XX

PA (USSH) US DEPT HEALTH & HUMAN SERVICES.

XX

PI Pastan I, Bera TK, Lee B;

XX

DR WPI; 2004-758338/74.

XX

PT New Splice Variant-Novel Gene Expressed in Prostate polypeptide or
 PT encoding nucleic acid molecule for diagnosing, preventing or treating
 PT cancer, especially prostate cancer.

XX

PS Disclosure; SEQ ID NO 6; 88pp; English.

XX

CC The present sequence is that of a predicted epitope of human splice
 CC variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope

CC is predicted to bind HLA2-01 and was identified using an HLA binding
 CC motif program. It corresponds to amino acids 846-854 of SV-NGEP.
 CC Polypeptides comprising an immunogenic fragment of 8 consecutive amino
 CC acids of SV-NGEP which specifically bind to an antibody that specifically
 CC binds a polypeptide comprising amino acids 157-933 of SV-NGEP are
 CC claimed. The invention provides methods for: detecting prostate cancer in
 CC a subject by contacting a sample with an antibody that specifically binds
 CC a SV-NGEP polypeptide and detecting the formation of an immune complex,
 CC or detecting an increase in expression of SV-NGEP polypeptide or mRNA;
 CC producing an immune response against a cell expressing SV-NGEP, for
 CC example in a subject with prostate cancer, by administering SV-NGEP
 CC polypeptide or polynucleotide to produce an immune response that
 CC decreases growth of the prostate cancer; inhibiting the growth of a
 CC malignant cell that expresses SV-NGEP by culturing cytotoxic T
 CC lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting
 CC these with the malignant cell; and inhibiting the growth of a malignant
 CC cell by contact with an antibody that specifically binds SV-NGEP, where
 CC the antibody is linked to a chemotherapeutic agent or toxin.

XX

SQ Sequence 9 AA;

Query Match 1.2%; Score 9; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 3.9e+06;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 690 LLAIRLAFV 698

|||||||

Db 1 LLAIRLAFV 9

RESULT 7

ADT77672

ID ADT77672 standard; peptide; 9 AA.

XX

AC ADT77672;

XX

DT 13-JAN-2005 (first entry)

XX

DE Splice variant-novel gene expressed in prostate (SV-NGEP) epitope.

XX

KW Splice variant-novel gene expressed in prostate; SV-NGEP; human;
 KW prostate cancer; cytostatic; gene therapy; immunotherapy; epitope.

XX

OS Homo sapiens.

XX

PN W02004092213-A1.

XX

PD 28-OCT-2004.

XX

PF 05-APR-2004; 2004WO-US010588.
 XX
 PR 08-APR-2003; 2003US-0461399P.
 XX
 PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
 XX
 PI Pastan I, Bera TK, Lee B;
 XX
 DR WPI; 2004-758338/74.
 XX
 PT New Splice Variant-Novel Gene Expressed in Prostate polypeptide or
 PT encoding nucleic acid molecule for diagnosing, preventing or treating
 PT cancer, especially prostate cancer.
 XX
 PS Disclosure; SEQ ID NO 9; 88pp; English.
 XX
 CC The present sequence is that of a predicted epitope of human splice
 CC variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope
 CC is predicted to bind HLA2-01 and was identified using an HLA binding
 CC motif program. It corresponds to amino acids 403-411 of SV-NGEP.
 CC Polypeptides comprising an immunogenic fragment of 8 consecutive amino
 CC acids of SV-NGEP which specifically bind to an antibody that specifically
 CC binds a polypeptide comprising amino acids 157-933 of SV-NGEP are
 CC claimed. The invention provides methods for: detecting prostate cancer in
 CC a subject by contacting a sample with an antibody that specifically binds
 CC a SV-NGEP polypeptide and detecting the formation of an immune complex,
 CC or detecting an increase in expression of SV-NGEP polypeptide or mRNA;
 CC producing an immune response against a cell expressing SV-NGEP, for
 CC example in a subject with prostate cancer, by administering SV-NGEP
 CC polypeptide or polynucleotide to produce an immune response that
 CC decreases growth of the prostate cancer; inhibiting the growth of a
 CC malignant cell that expresses SV-NGEP by culturing cytotoxic T
 CC lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting
 CC these with the malignant cell; and inhibiting the growth of a malignant
 CC cell by contact with an antibody that specifically binds SV-NGEP, where
 CC the antibody is linked to a chemotherapeutic agent or toxin.
 XX
 SQ Sequence 9 AA;

Query Match 1.2%; Score 9; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 3.9e+06;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 247 WLLSSACAL 255
 |||||
 Db 1 WLLSSACAL 9

RESULT 8

ADT77667

ID ADT77667 standard; peptide; 9 AA.

XX

AC ADT77667;

XX

DT 13-JAN-2005 (first entry)

XX

DE Splice variant-novel gene expressed in prostate (SV-NGEP) epitope.

XX

KW Splice variant-novel gene expressed in prostate; SV-NGEP; human;
KW prostate cancer; cytostatic; gene therapy; immunotherapy; epitope.

XX

OS Homo sapiens.

XX

PN W02004092213-A1.

XX

PD 28-OCT-2004.

XX

PF 05-APR-2004; 2004WO-US010588.

XX

PR 08-APR-2003; 2003US-0461399P.

XX

PA (USSH) US DEPT HEALTH & HUMAN SERVICES.

XX

PI Pastan I, Bera TK, Lee B;

XX

DR WPI; 2004-758338/74.

XX

PT New Splice Variant-Novel Gene Expressed in Prostate polypeptide or
PT encoding nucleic acid molecule for diagnosing, preventing or treating
PT cancer, especially prostate cancer.

XX

PS Disclosure; SEQ ID NO 4; 88pp; English.

XX

CC The present sequence is that of a predicted epitope of human splice
 CC variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope
 CC is predicted to bind HLA2-01 and was identified using an HLA binding
 CC motif program. It corresponds to amino acids 215-223 of SV-NGEP.
 CC Polypeptides comprising an immunogenic fragment of 8 consecutive amino
 CC acids of SV-NGEP which specifically bind to an antibody that specifically
 CC binds a polypeptide comprising amino acids 157-933 of SV-NGEP are
 CC claimed. The invention provides methods for: detecting prostate cancer in
 CC a subject by contacting a sample with an antibody that specifically binds
 CC a SV-NGEP polypeptide and detecting the formation of an immune complex,
 CC or detecting an increase in expression of SV-NGEP polypeptide or mRNA;
 CC producing an immune response against a cell expressing SV-NGEP, for
 CC example in a subject with prostate cancer, by administering SV-NGEP
 CC polypeptide or polynucleotide to produce an immune response that
 CC decreases growth of the prostate cancer; inhibiting the growth of a

CC malignant cell that expresses SV-NGEP by culturing cytotoxic T
 CC lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting
 CC these with the malignant cell; and inhibiting the growth of a malignant
 CC cell by contact with an antibody that specifically binds SV-NGEP, where
 CC the antibody is linked to a chemotherapeutic agent or toxin.
 XX
 SQ Sequence 9 AA;

Query Match 1.2%; Score 9; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 3.9e+06;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 59 VLLEVVDPDV 67
 |||||
 Db 1 VLLEVVDPDV 9

RESULT 9

AAG95042

ID AAG95042 standard; peptide; 10 AA.

XX

AC AAG95042;

XX

DT 18-SEP-2001 (first entry)

XX

DE Human complementary peptide, SEQ ID NO: 1236.

XX

KW Human; complementary peptide; ligand; drug discovery; drug design.

XX

OS Homo sapiens.

XX

PN WO200142277-A2.

XX

PD 14-JUN-2001.

XX

PF 13-DEC-2000; 2000WO-GB004776.

XX

PR 13-DEC-1999; 99GB-00029464.

XX

PA (PROT-) PROTEOM LTD.

XX

PI Roberts GW, Heal JR;

XX

DR WPI; 2001-408419/43.

XX

PT A set of peptide ligands consisting of specific complementary peptides to
 PT proteins encoded by genes of the human genome, useful in an assay for
 PT screening and identifying of one or more novel peptides which are drug
 PT candidates or pro-drugs.

XX
PS Example 4; Page 217; 646pp; English.

XX
CC The invention relates to a set of complementary peptide ligands generated
CC from the human genome. The complementary peptides interact with their
CC relevant target proteins encoded in the human genome. They can be used as
CC reagents in drug discovery and as lead ligands to facilitate drug design
CC and development. The present sequence is a complementary peptide provided
CC in the specification

XX
SQ Sequence 10 AA;

Query Match 1.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 8.6;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 525 AGASAGAS 532
|||||||
Db 1 AGASAGAS 8

RESULT 10

AAG97554

ID AAG97554 standard; peptide; 10 AA.

XX Does not bind MHC /LBG/
AC AAG97554;

XX
DT 18-SEP-2001 (first entry)

XX
DE Human complementary peptide, SEQ ID NO: 3749.

XX
KW Human; complementary peptide; ligand; drug discovery; drug design.

XX
OS Homo sapiens.

XX
PN WO200142277-A2.

XX
PD 14-JUN-2001.

XX
PF 13-DEC-2000; 2000WO-GB004776.

XX
PR 13-DEC-1999; 99GB-00029464.

XX
PA (PROT-) PROTEOM LTD.

XX
PI Roberts GW, Heal JR;

XX
DR WPI; 2001-408419/43.

XX

PT A set of peptide ligands consisting of specific complementary peptides to
 PT proteins encoded by genes of the human genome, useful in an assay for
 PT screening and identifying of one or more novel peptides which are drug
 PT candidates or pro-drugs.

XX
 PS Example 6; Page 581; 646pp; English.

XX
 CC The invention relates to a set of complementary peptide ligands generated
 CC from the human genome. The complementary peptides interact with their
 CC relevant target proteins encoded in the human genome. They can be used as
 CC reagents in drug discovery and as lead ligands to facilitate drug design
 CC and development. The present sequence is a complementary peptide provided
 CC in the specification

XX
 SQ Sequence 10 AA;

Query Match 1.0%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 8.6;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 525 AGASAGAS 532
 |||||
 Db 1 AGASAGAS 8

RESULT 11

AAG97553

ID AAG97553 standard; peptide; 10 AA.

XX
 AC AAG97553; Does not bind MHC /LBG/

XX
 DT 18-SEP-2001 (first entry)

XX
 DE Human complementary peptide, SEQ ID NO: 3748.

XX
 KW Human; complementary peptide; ligand; drug discovery; drug design.

XX
 OS Homo sapiens.

XX
 PN WO200142277-A2.

XX
 PD 14-JUN-2001.

XX
 PF 13-DEC-2000; 2000WO-GB004776.

XX
 PR 13-DEC-1999; 99GB-00029464.

XX
 PA (PROT-) PROTEOM LTD.

XX

PI Roberts GW, Heal JR;
 XX
 DR WPI; 2001-408419/43.
 XX
 PT A set of peptide ligands consisting of specific complementary peptides to
 PT proteins encoded by genes of the human genome, useful in an assay for
 PT screening and identifying of one or more novel peptides which are drug
 PT candidates or pro-drugs.
 XX
 PS Example 6; Page 581; 646pp; English.
 XX
 CC The invention relates to a set of complementary peptide ligands generated
 CC from the human genome. The complementary peptides interact with their
 CC relevant target proteins encoded in the human genome. They can be used as
 CC reagents in drug discovery and as lead ligands to facilitate drug design
 CC and development. The present sequence is a complementary peptide provided
 CC in the specification
 XX
 SQ Sequence 10 AA;

Query Match 1.0%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 8.6;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 525 AGASAGAS 532
 |||||
 Db 1 AGASAGAS 8

Search completed: March 17, 2009, 20:59:10
 Job time : 136 secs

SCORE 3.0